These future studies should address the uncertainties raised in previous evidence, particularly regarding the role of GLP-1 in disease progression, its mechanism of action, and its safety profile, to further clarify the potential of GLP-1 receptor agonists as a therapeutic option in PD. Here, GCG is linked to Parkinson disease.